Moderna, a leading biotechnology company, has received a substantial financial boost from the US Department of Health & Human Services (HHS) to speed up the development of an mRNA-based vaccine for bird flu. The award amounts to approximately 590 million dollars, fueling research and production efforts to combat the potential outbreak of a human pandemic.